http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#Head
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#assertion
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#provenance
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#pubinfo
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#assertion
http://purl.obolibrary.org/obo/DOID_1406
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_1406
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00873
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#association
http://www.w3.org/2000/01/rdf-schema#label
loteprednol etabonate is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva cornea and anterior segment of the globe such as allergic conjunctivitis acne rosacea superficial punctate keratitis herpes zoster keratitis iritis cyclitis selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation loteprednol etabonate is less effective than prednisolone acetate 1 in two 28 day controlled clinical studies in acute anterior uveitis where 72 of patients treated with loteprednol etabonate experienced resolution of anterior chamber cells compared to 87 of patients treated with prednisolone acetate 1 the incidence of patients with clinically significant increases in iop 1 mmhg was 1 with loteprednol etabonate and 6 with prednisolone acetate 1 loteprednol etabonate should not be used in patients who require a more potent corticosteroid for this indication loteprednol etabonate is also indicated for the treatment of post operative inflammation following ocular surgery
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00873
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#provenance
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#pubinfo
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#sig
http://purl.org/nanopub/x/hasSignature
NA47n7lIaDTmZr3Sy3Iim1W0yz8c5goZgQ8WF9DnJu34LYUq53OYovD9JXwECWP262+Vjx7SaVhEYfKwHYRA06netMCso5ziD7tsFz725VSOy7JMtPXNclq4+KSy2/H4dGnjUAppvqQ2kFUjkaKt81FDR7n9My0z0CGzS8dXk9A=
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto
http://purl.org/dc/terms/created
2021-06-12T15:45:39.687+02:00
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs